US Pharma MarketingThe post Valar Labs hits US first with breakthrough designation for AI bladder cancer test appeared first on Medical Device Network.
Valar Labs hits US first with breakthrough designation for AI bladder cancer test
Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained pathology slides. Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained pathology slides. Bladder cancer is the tenth leading cause of cancer death in the US. Credit: mi_viri / Shutterstock.com Valar Labs’ Vesta Bladder Risk Stratify Dx has secured breakthrough device designation from the US Food and Drug Administration (FDA), becoming the first artificial intelligence (AI)-based digital pathology prognostic test in bladder cancer to receive the tag. The California-based company’s Vesta Bladder Risk Stratify Dx…
Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained pathology slides.
Source: Medical Device Network